What is IMA's relative strength rating?

IMA ranks at the 44th percentile over 1 month, 51th percentile over 3 months, 30th percentile over 6 months, 12th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is IMA in?

IMA is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is IMA in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). IMA benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

IMA currently shows a 20-day average daily range (ADR%) of 5.6%, a 90-day beta versus the S&P 500 of 1.14. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does IMA have a seasonal pattern?

TickerStance computes IMA's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what IMA has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did IMA last report earnings?

IMA most recently filed a 10-Q covering FY26 Q2 with the SEC on 2026-08-05. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.

ImageneBio, Inc. Common Stock (IMA) · RS 30

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, ImageneBio, Inc. Common Stock (IMA) has a 3-month relative strength percentile of 51 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 42. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.6%, relative volume 1.37×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month51pctile

6 month30pctile

1 year12pctile

Classic21IBD pctile

LDR12leadership

0 of 5 lenses lit · avg RS pctile 25

✓ADR%5.6%!A/DD!RVOL1.37×!$ Vol$63K

COMPUTED · AS OF 2026-08-24

Pattern read

IMA is in a stage 4 downtrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -2.8% / -9.1%.

Pure factual computation. Not a recommendation. See stage analysis.

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

Evidence · 1 of 3

Receipts behind the read

0 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

44

3m

51

6m

30

1y

12

LDR

—

StageWeinstein stage analysis

Stage 4 · Decline

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

Fundamentals · IMA

Does the business back the chart?

SEC EDGAR · last filing 10-Q · FY26 Q2 · period end 2026-06-30

1

Fundamentals Growth Rank

How does growth rank vs. the universe?

vs. 4,480 ranked stocks · Sector rank 2

View fundamental leadership map

Laggard

Earnings

Are losses narrowing?

Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.

Loss widening

−$0.21—

24 Q3

−$0.20—

24 Q4

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
IMA
51RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

CTXRCitius Pharmaceuticals Inc. Common30 VRCAVerrica Pharmaceuticals Inc. Common Stock30 GERNGeron Corp30 MGXMetagenomi Therapeutics, Inc. Common Stock29

§ Seasonality

10y · since 2025

Best monthApr on averageavg +20.40% · 100% win · n 1

Worst monthSep on averageavg -39.18% · 0% win · n 1

IMA monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	IMA Jan avg: 8.84% median: 8.84% win: 100% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA Feb avg: -10.52% median: -10.52% win: 0% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA Mar avg: -25.60% median: -25.60% win: 0% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA Apr avg: 20.40% median: 20.40% win: 100% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA May avg: -2.33% median: -2.33% win: 0% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA Jun avg: 0.34% median: 0.34% win: 100% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA Jul avg: 1.62% median: 1.62% win: 50% σ: 10.92% n: 2 2025-07-29 → 2026-07-31	IMA Aug avg: -25.14% median: -25.14% win: 0% σ: 0.00% n: 1 2025-07-29 → 2026-07-31 (current)	IMA Sep avg: -39.18% median: -39.18% win: 0% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA Oct avg: 6.87% median: 6.87% win: 100% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA Nov avg: -20.78% median: -20.78% win: 0% σ: 0.00% n: 1 2025-07-29 → 2026-07-31	IMA Dec avg: 0.00% median: 0.00% win: 100% σ: 0.00% n: 1 2025-07-29 → 2026-07-31

ETF OWNERS

ETFs holding IMA

IMA is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $1M notional.

Held by 3 ETFs · $2M across latest filings · largest weight 0.02% (IWC).

ETFs holding: 2
Total value: $2M
Top 3 concentration: 100.0%
Max weight: VXF · 0.00%

Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.

ETFs holding IMA ranked by value
ETF	Weight	Value	Δ
VTIVanguard Total Stock Market ETF	0.00%	$1M	—
VXFVanguard Extended Market ETF	0.00%	$263K	—

IWC new

As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.

Public attention · IMA

Is the crowd watching?

44/ 100 · vs its own 90-day norm▼ 1 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2836

Float9.0Mshares

Shares out11.4Mshares

Market cap$63.8MMicro Cap

FAQ

Frequently asked questions

What is IMA's relative strength rating?: IMA ranks at the 44th percentile over 1 month, 51th percentile over 3 months, 30th percentile over 6 months, 12th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is IMA in?: IMA is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is IMA in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). IMA benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is IMA?: IMA currently shows a 20-day average daily range (ADR%) of 5.6%, a 90-day beta versus the S&P 500 of 1.14. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does IMA have a seasonal pattern?: TickerStance computes IMA's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what IMA has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

ImageneBio, Inc. Common Stock (IMA) — Stance & relative strength

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

§ Seasonality

ETFs holding IMA

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?

§ Seasonality

ImageneBio, Inc. Common Stock (IMA) — Stance & relative strength

IMA is not confirmed as a leader. 51 is not yet a leadership-grade RS read, Market Stance is 47.8

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

ETFs holding IMA

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?